Evidence map›Paper›PMID 37822938›Full record

ArticleFrontiers in immunology2023

Short-term assays for mesenchymal stromal cell immunosuppression of T-lymphocytes.

Maryanne C Herzig, Barbara A Christy, Robbie K Montgomery, Carolina Cantu-Garza, Gema D Barrera, Ji H Lee, Nicholas Mucha, Jennifer R Talackine, Isaac A Abaasah, James A Bynum and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Cell Therapies for Acute Radiation Syndrome.International journal of molecular sciences · 2024
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Maryanne C HerzigBlood and Shock Research, US Army Institute of Surgical Research, Fort Sam Houston, TX, United States.
Barbara A ChristyBlood and Shock Research, US Army Institute of Surgical Research, Fort Sam Houston, TX, United States.
Robbie K MontgomeryBlood and Shock Research, US Army Institute of Surgical Research, Fort Sam Houston, TX, United States.
Carolina Cantu-GarzaBlood and Shock Research, US Army Institute of Surgical Research, Fort Sam Houston, TX, United States.
Gema D BarreraBlood and Shock Research, US Army Institute of Surgical Research, Fort Sam Houston, TX, United States.
Ji H LeeBlood and Shock Research, US Army Institute of Surgical Research, Fort Sam Houston, TX, United States.
Nicholas MuchaBlood and Shock Research, US Army Institute of Surgical Research, Fort Sam Houston, TX, United States.
Jennifer R TalackineBlood and Shock Research, US Army Institute of Surgical Research, Fort Sam Houston, TX, United States.
Isaac A AbaasahBlood and Shock Research, US Army Institute of Surgical Research, Fort Sam Houston, TX, United States.
James A BynumBlood and Shock Research, US Army Institute of Surgical Research, Fort Sam Houston, TX, United States.
Andrew P CapBlood and Shock Research, US Army Institute of Surgical Research, Fort Sam Houston, TX, United States.
United States Army Institute of Surgical Research · USThe University of Texas Health Science Center at San Antonio · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Trauma patients are susceptible to coagulopathy and dysfunctional immune responses. Mesenchymal stromal cells (MSCs) are at the forefront of the cellular therapy revolution with profound immunomodulatory, regenerative, and therapeutic potential. Routine assays to assess immunomodulation activity examine MSC effects on proliferation of peripheral blood mononuclear cells (PBMCs) and take 3-7 days. Assays that could be done in a shorter period of time would be beneficial to allow more rapid comparison of different MSC donors. The studies presented here focused on assays for MSC suppression of mitogen-stimulated PBMC activation in time frames of 24 h or less. Methods: Three potential assays were examined-assays of apoptosis focusing on caspase activation, assays of phosphatidyl serine externalization (PS+) on PBMCs, and measurement of tumor necrosis factor alpha (TNFα) levels using rapid ELISA methods. All assays used the same initial experimental conditions: cryopreserved PBMCs from 8 to 10 pooled donors, co-culture with and without MSCs in 96-well plates, and PBMC stimulation with mitogen for 2-72 h. Results: Suppression of caspase activity in activated PBMCs by incubation with MSCs was not robust and was only significant at times after 24 h. Monitoring PS+ of live CD3+ or live CD4+/CD3+ mitogen-activated PBMCs was dose dependent, reproducible, robust, and evident at the earliest time point taken, 2 h, although no increase in the percentage of PS+ cells was seen with time. The ability of MSC in co-culture to suppress PBMC PS+ externalization compared favorably to two concomitant assays for MSC co-culture suppression of PBMC proliferation, at 72 h by ATP assay, or at 96 h by fluorescently labeled protein signal dilution. TNFα release by mitogen-activated PBMCs was dose dependent, reproducible, robust, and evident at the earliest time point taken, with accumulating signal over time. However, suppression levels with MSC co-culture was reliably seen only after 24 h. Discussion: Takeaways from these studies are as follows: (1) while early measures of PBMC activation is evident at 2-6 h, immunosuppression was only reliably detected at 24 h; (2) PS externalization at 24 h is a surrogate assay for MSC immunomodulation; and (3) rapid ELISA assay detection of TNFα release by PBMCs is a robust and sensitive assay for MSC immunomodulation at 24 h.

Indexed as

Mesenchymal Stem CellsT-LymphocytesCaspasesHumansImmunosuppression TherapyIntercellular Signaling Peptides and ProteinsLeukocytes, MononuclearMitogensTumor Necrosis Factor-alphaCaspasesIntercellular Signaling Peptides and ProteinsMitogensTumor Necrosis Factor-alphacaspasecytokineIL-6mesenchymal stromal cellperipheral blood mononuclear cellsphosphatidyl serinetNF-alpha

Identifiers

PMID37822938
PMCPMC10562633
OpenAlexW4387100719

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.